|
Name |
Calbistrin G
|
Molecular Formula | C28H44O8 | |
IUPAC Name* |
[(1S,3R,4aR,7S,8S,8aS)-8-(2,3-dihydroxypropanoyl)-3,7,8-trimethyl-2,3,4,4a,7,8a-hexahydro-1H-naphthalen-1-yl] (2S,3R,4E,6E,8S,9R)-3,8,9-trihydroxy-2,4-dimethyldeca-4,6-dienoate
|
|
SMILES |
C[C@@H]1C[C@@H]2C=C[C@@H]([C@]([C@H]2[C@H](C1)OC(=O)[C@@H](C)[C@H](/C(=C/C=C/[C@@H]([C@@H](C)O)O)/C)O)(C)C(=O)C(CO)O)C
|
|
InChI |
InChI=1S/C28H44O8/c1-15-12-20-11-10-17(3)28(6,26(34)22(32)14-29)24(20)23(13-15)36-27(35)18(4)25(33)16(2)8-7-9-21(31)19(5)30/h7-11,15,17-25,29-33H,12-14H2,1-6H3/b9-7+,16-8+/t15-,17+,18+,19-,20+,21+,22?,23+,24-,25+,28+/m1/s1
|
|
InChIKey |
ASHQRLOFJNKMPY-NKJZOWFESA-N
|
|
Synonyms |
Calbistrin G; CHEMBL3358713; [(1S,3R,4aR,7S,8S,8aS)-8-(2,3-dihydroxypropanoyl)-3,7,8-trimethyl-2,3,4,4a,7,8a-hexahydro-1H-naphthalen-1-yl] (2S,3R,4E,6E,8S,9R)-3,8,9-trihydroxy-2,4-dimethyl-deca-4,6-dienoate
|
|
CAS | NA | |
PubChem CID | 118723027 | |
ChEMBL ID | CHEMBL3358713 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 508.6 | ALogp: | 2.5 |
HBD: | 5 | HBA: | 8 |
Rotatable Bonds: | 11 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 145.0 | Aromatic Rings: | 2 |
Heavy Atoms: | 36 | QED Weighted: | 0.172 |
Caco-2 Permeability: | -5.145 | MDCK Permeability: | 0.00023443 |
Pgp-inhibitor: | 0.089 | Pgp-substrate: | 0.998 |
Human Intestinal Absorption (HIA): | 0.066 | 20% Bioavailability (F20%): | 0.021 |
30% Bioavailability (F30%): | 0.925 |
Blood-Brain-Barrier Penetration (BBB): | 0.132 | Plasma Protein Binding (PPB): | 53.47% |
Volume Distribution (VD): | 0.423 | Fu: | 15.60% |
CYP1A2-inhibitor: | 0.055 | CYP1A2-substrate: | 0.109 |
CYP2C19-inhibitor: | 0.015 | CYP2C19-substrate: | 0.753 |
CYP2C9-inhibitor: | 0.006 | CYP2C9-substrate: | 0.27 |
CYP2D6-inhibitor: | 0.002 | CYP2D6-substrate: | 0.082 |
CYP3A4-inhibitor: | 0.613 | CYP3A4-substrate: | 0.275 |
Clearance (CL): | 3.333 | Half-life (T1/2): | 0.738 |
hERG Blockers: | 0.084 | Human Hepatotoxicity (H-HT): | 0.804 |
Drug-inuced Liver Injury (DILI): | 0.854 | AMES Toxicity: | 0.021 |
Rat Oral Acute Toxicity: | 0.415 | Maximum Recommended Daily Dose: | 0.017 |
Skin Sensitization: | 0.116 | Carcinogencity: | 0.077 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.014 |
Respiratory Toxicity: | 0.884 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003294 | 0.856 | D02RQU | 0.257 | ||||
ENC003292 | 0.825 | D0E9KA | 0.229 | ||||
ENC004660 | 0.338 | D06WTZ | 0.215 | ||||
ENC003895 | 0.328 | D0X7XG | 0.198 | ||||
ENC003665 | 0.321 | D06PTA | 0.191 | ||||
ENC004127 | 0.319 | D0S0AS | 0.191 | ||||
ENC004128 | 0.310 | D0F7NQ | 0.191 | ||||
ENC003132 | 0.291 | D0G7KJ | 0.190 | ||||
ENC003119 | 0.286 | D03IKT | 0.189 | ||||
ENC003817 | 0.277 | D0H0ND | 0.188 |